This means that monitoring YY1 and RKIP gene expressions—both alone and in combination as a two-gene signature—might really help to tackle the prognostic window, as well as to match the specific genetic features of each single lung adenocarcinoma patient, with the final goal of suggesting a personalized therapeutic protocol. Here, YY1 is linked to lung adenocarcinoma.